- AbbVie has raised its full-year adjusted EPS forecast to a range of $11.88 to $12.08, compared to the previous expectation of $11.67 to $11.87.
- In the second quarter, AbbVie reported a net revenue increase of 6.6% year-over-year, reaching $15.42 billion, surpassing the estimate of $15 billion.
- Second quarter adjusted EPS was $2.97, up from $2.65 in the same period last year.
- Humira revenue came in at $1.18 billion, below the estimated $1.42 billion.
- Skyrizi’s revenue significantly exceeded expectations, reaching $4.42 billion against an estimate of $4.03 billion.
- Rinvoq generated $2.03 billion in revenue, slightly above its $1.99 billion estimate.
- Imbruvica revenue was $754 million, surpassing the $713.4 million estimate.
- Venclexta achieved revenue of $691 million, outperforming the $673.4 million expectation.
- Botox – Cosmetic revenue matched closely with estimates at $692 million, compared to an estimate of $691 million.
- Botox – Therapeutic revenue reached $928 million, above the estimated $893.2 million.
- Revenue from Vraylar was $900 million, over the $838.5 million forecast.
- Ubrelvy’s revenue was $338 million, significantly surpassing the expected $273.7 million.
- Creon revenue also exceeded expectations, reporting $404 million against an estimate of $386.5 million.
- The results were impacted by an unfavorable $0.42 per share expense related to acquired in-process research and development (IPR&D) and milestones.
- The full-year EPS forecast includes an adverse impact of $0.55 per share due to the same IPR&D and milestones expense incurred up to the second quarter of 2025.
Abbvie Inc on Smartkarma
Analyst coverage of AbbVie Inc on Smartkarma reveals positive sentiments and insightful analysis from Baptista Research analysts. In one report titled “AbbVie’s Bold Obesity Play Could Up Its Game In the GLP-1 Domain—Here’s What You Need to Know!”, the analysts highlight AbbVie’s strong performance in the first quarter of 2025. The company exceeded expectations with adjusted earnings per share of $2.46 and total net revenues surpassing $13.3 billion.
Another report by Baptista Research, “AbbVie Inc.: An Analysis Of Its Immunology Market Expansion, Oncology Pipeline & ADC Strategy!“, underscores AbbVie’s robust performance in 2024 despite challenges such as Humira sales erosion. The company’s total revenue of $56.3 billion exceeded initial guidance by over $2 billion, with adjusted earnings per share reaching $10.12. The report also emphasizes the significant growth demonstrated by AbbVie’s “ex-Humira” platform, driven by products like Skyrizi and Rinvoq.
A look at Abbvie Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 2 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Abbvie Inc. has received a mix of Smartkarma Smart Scores for its overall outlook. With a solid Dividend score of 4 and a respectable Resilience score of 3, the company demonstrates strength in these areas for potential long-term investors. However, with Value and Growth scores of 2 each, Abbvie may not be seen as a top-tier choice for those seeking high-value or strong growth potential.
Additionally, Abbvie Inc. holds a Momentum score of 3, indicating moderate momentum in the market. Overall, based on the Smartkarma Smart Scores, investors may find Abbvie Inc. to be a dependable choice for dividends and resilience in the pharmaceutical industry, despite middling scores in value and growth factors.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
